S. Wild, A. Green, R. Sicree, and H. King, Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030, Diabetes Care, vol.27, issue.5, pp.1047-1053, 2004.
DOI : 10.2337/diacare.27.5.1047

D. Nathan, J. Buse, M. Davidson, E. Ferrannini, and R. Holman, Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, vol.32, issue.1, pp.193-203, 2009.
DOI : 10.2337/dc08-9025

A. Saenz, I. Fernandez-esteban, A. Mataix, A. Segura, M. et al., Metformin monotherapy for type 2 diabetes mellitus, Cochrane Database Syst Rev, p.2966, 2005.

E. Selvin, S. Bolen, H. Yeh, C. Wiley, and L. Wilson, Cardiovascular Outcomes in Trials of Oral Diabetes Medications, Archives of Internal Medicine, vol.168, issue.19, pp.2070-2080, 2008.
DOI : 10.1001/archinte.168.19.2070

W. Bennett, N. Maruthur, S. Singh, J. Segal, and L. Wilson, Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations, Annals of Internal Medicine, vol.154, issue.9, pp.602-613, 2011.
DOI : 10.7326/0003-4819-154-9-201105030-00336

C. Lamanna, M. Monami, N. Marchionni, and E. Mannucci, Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials, Diabetes, Obesity and Metabolism, vol.46, issue.3, pp.221-228, 2011.
DOI : 10.1111/j.1463-1326.2010.01349.x

R. Rachmani, I. Slavachevski, Z. Levi, B. Zadok, and Y. Kedar, Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications, European Journal of Internal Medicine, vol.13, issue.7, pp.428-433, 2002.
DOI : 10.1016/S0953-6205(02)00131-0

D. Cryer, D. Mills, S. Nicholas, B. Stadel, and D. Henry, Comparative Outcomes Study of Metformin Intervention Versus Conventional Approach The COSMIC Approach Study, Diabetes Care, vol.28, issue.3, pp.539-543, 2005.
DOI : 10.2337/diacare.28.3.539

A. Jadad, R. Moore, D. Carroll, C. Jenkinson, and D. Reynolds, Assessing the quality of reports of randomized clinical trials: Is blinding necessary?, Controlled Clinical Trials, vol.17, issue.1, pp.1-12, 1996.
DOI : 10.1016/0197-2456(95)00134-4

J. Higgins and S. Thompson, Quantifying heterogeneity in a meta-analysis, Statistics in Medicine, vol.14, issue.11, pp.1539-1558, 2002.
DOI : 10.1002/sim.1186

G. Rücker, G. Schwarzer, J. Carpenter, and M. Schumacher, Undue reliance on I 2 in assessing heterogeneity may mislead, BMC Medical Research Methodology, vol.176, issue.8, p.79, 2008.
DOI : 10.1503/cmaj.060410

A. Kooy, D. Jager, J. Lehert, P. Bets, D. Wulffelé et al., Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus, Archives of Internal Medicine, vol.169, issue.6, pp.616-625, 2009.
DOI : 10.1001/archinternmed.2009.20

B. Teupe and K. Bergis, Prospective randomised two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes, Diabete Metab, vol.17, pp.213-217, 1991.

L. Hermann, B. Scherstén, P. Bitzén, T. Kjellström, and F. Lindgä-rde, Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations: A double-blind controlled study, Diabetes Care, vol.17, issue.10, pp.1100-1109, 1994.
DOI : 10.2337/diacare.17.10.1100

E. Horton, J. Foley, C. Clinkingbeard, S. Mallows, and M. Gatlin, Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes, Diabetes Care, vol.23, issue.11, pp.1660-1665, 2000.
DOI : 10.2337/diacare.23.11.1660

L. Hermann, J. Kalén, P. Katzman, I. Lager, and A. Nilsson, Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients, Diabetes, Obesity and Metabolism, vol.20, issue.Suppl., pp.428-434, 2001.
DOI : 10.1046/j.1463-1326.2001.00160.x

K. Hä-llsten, K. Virtanen, F. Lönnqvist, H. Sipilä, and A. Oksanen, Rosiglitazone but Not Metformin Enhances Insulin- and Exercise-Stimulated Skeletal Muscle Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes, Diabetes, vol.51, issue.12, pp.3479-3485, 2002.
DOI : 10.2337/diabetes.51.12.3479

A. Garber, D. Donovan, P. Dandona, S. Bruce, and J. Park, Efficacy of Glyburide/Metformin Tablets Compared with Initial Monotherapy in Type 2 Diabetes, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.8, pp.3598-3604, 2003.
DOI : 10.1210/jc.2002-021225

L. Blonde, J. Rosenstock, A. Mooradian, B. Piper, and D. Henry, Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy, Diabetes, Obesity and Metabolism, vol.49, issue.6, pp.368-375, 2002.
DOI : 10.1007/s005920050146

R. Defronzo and A. Goodman, Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus, New England Journal of Medicine, vol.333, issue.9, pp.541-549, 1995.
DOI : 10.1056/NEJM199508313330902

J. Chiasson and L. Nadtich, The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes, Diabetes Care, vol.24, issue.6, pp.989-994, 2001.
DOI : 10.2337/diacare.24.6.989

S. Greenberg, How citation distortions create unfounded authority: analysis of a citation network Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, BMJ ADVANCE Collaborative Group N Engl J Med, vol.339, issue.358, pp.2560-2572, 2008.

P. Home, S. Pocock, H. Beck-nielsen, P. Curtis, and R. Gomis, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial, The Lancet, vol.373, issue.9681, pp.2125-2135, 2009.
DOI : 10.1016/S0140-6736(09)60953-3

L. Azoulay, V. Schneider-lindner, S. Schiffrin, A. Suissa, and S. , Combination therapy with sulphonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study, Pharmacoepidemiol Drug Saf, vol.19, pp.335-342, 2010.

C. Andersson, J. Olesen, P. Hansen, P. Weeke, and M. Norgaard, Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study, Diabetologia, vol.44, issue.12, pp.2546-2553, 2010.
DOI : 10.1007/s00125-010-1906-6

B. Sillars, W. Davis, I. Hirsch, and T. Davis, Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study, Diabetes, Obesity and Metabolism, vol.5, issue.9, pp.757-765, 2010.
DOI : 10.1111/j.1463-1326.2010.01230.x

A. Rao, N. Kuhadiya, K. Reynolds, and V. Fonseca, Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?: A meta-analysis of observational studies, Diabetes Care, vol.31, issue.8, pp.1672-1678, 2008.
DOI : 10.2337/dc08-0167

D. Nathan, Some answers, more controversy, from UKPDS, The Lancet, vol.352, issue.9131, pp.832-833, 1998.
DOI : 10.1016/S0140-6736(98)22937-0

R. Ewart, The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study Commentary: UKPDS is well designed and clinically important, BMJ, vol.323, issue.7317, pp.854-858, 2001.
DOI : 10.1136/bmj.323.7317.854

J. Mccormack and T. Greenhalgh, Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data, BMJ, vol.320, issue.7251, pp.1720-1723, 2000.
DOI : 10.1136/bmj.320.7251.1720

K. Schulz, I. Chalmers, R. Hayes, and D. Altman, Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials, JAMA: The Journal of the American Medical Association, vol.273, issue.5, pp.408-412, 1995.
DOI : 10.1001/jama.273.5.408

D. Moher, B. Pham, A. Jones, D. Cook, and A. Jadad, Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?, The Lancet, vol.352, issue.9128, pp.609-613, 1998.
DOI : 10.1016/S0140-6736(98)01085-X

R. Holman, D. Matthews, and H. Neil, Follow-up of intensive glucose control in type 2 diabetes. The authors reply, N Engl J Med, vol.360, pp.416-418, 2009.

J. Hirst, A. Farmer, R. Ali, N. Roberts, and R. Stevens, Quantifying the Effect of Metformin Treatment and Dose on Glycemic Control, Diabetes Care, vol.35, issue.2, pp.446-454, 2012.
DOI : 10.2337/dc11-1465

A. Shaughnessy and D. Slawson, What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes, BMJ, vol.327, issue.7409, pp.266-273, 2003.
DOI : 10.1136/bmj.327.7409.266

G. Gandhi, M. Murad, A. Fujiyoshi, R. Mullan, and D. Flynn, Patient-Important Outcomes in Registered Diabetes Trials, JAMA, vol.299, issue.21, pp.2543-2549, 2008.
DOI : 10.1001/jama.299.21.2543

R. Prentice, Surrogate endpoints in clinical trials: Definition and operational criteria, Statistics in Medicine, vol.248, issue.4, pp.431-440, 1989.
DOI : 10.1002/sim.4780080407

E. Fitzgerald, S. Mathieu, and A. Ball, Metformin associated lactic acidosis, BMJ, vol.339, issue.sep16 2, 2009.
DOI : 10.1136/bmj.b3660

D. Jager, J. Kooy, A. Lehert, P. Wulffelé, M. Van-der-kolk et al., Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial, BMJ, vol.340, issue.may19 4, 2010.
DOI : 10.1136/bmj.c2181

I. Tzoulaki, M. Molokhia, V. Curcin, M. Little, and C. Millett, Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database, BMJ, vol.339, issue.dec03 1, 2009.
DOI : 10.1136/bmj.b4731

J. Gamble, S. Simpson, D. Eurich, S. Majumdar, and J. Johnson, Insulin use and increased risk of mortality in type 2 diabetes: a cohort study, Diabetes, Obesity and Metabolism, vol.25, issue.1, pp.47-53, 2010.
DOI : 10.1111/j.1463-1326.2009.01125.x

D. Eurich, F. Mcalister, D. Blackburn, S. Majumdar, and R. Tsuyuki, Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review, BMJ, vol.335, issue.7618, p.497, 2007.
DOI : 10.1136/bmj.39314.620174.80

S. Bowker, S. Majumdar, P. Veugelers, and J. Johnson, Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin, Diabetes Care, vol.29, issue.2, pp.254-258, 2006.
DOI : 10.2337/diacare.29.02.06.dc05-1558

C. Currie, C. Poole, and E. Gale, The influence of glucose-lowering therapies on cancer risk in type 2 diabetes, Diabetologia, vol.23, issue.9, pp.1766-1777, 2009.
DOI : 10.1007/s00125-009-1440-6

S. Nissen and K. Wolski, Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes, New England Journal of Medicine, vol.356, issue.24, pp.2457-2471, 2007.
DOI : 10.1056/NEJMoa072761

B. Richter, E. Bandeira-echtler, K. Bergerhoff, C. Clar, and S. Ebrahim, Pioglitazone for type 2 diabetes mellitus, Cochrane Database Syst Rev, vol.15, issue.1, p.6060, 2006.
DOI : 10.1002/14651858.CD006060.pub2

R. Roussel, F. Travert, B. Pasquet, P. Wilson, S. Smith et al., Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis<alt-title>Metformin Use With Diabetes and Atherothrombosis</alt-title>, Archives of Internal Medicine, vol.170, issue.21, pp.1892-1899, 2010.
DOI : 10.1001/archinternmed.2010.409